PubRank

Anthony Atala

Author PubWeight™ 355.14‹?›

Top papers

Rank Title Journal Year PubWeight™‹?›
1 Isolation of amniotic stem cell lines with potential for therapy. Nat Biotechnol 2007 9.67
2 Tissue-engineered autologous urethras for patients who need reconstruction: an observational study. Lancet 2011 3.95
3 Engineering complex tissues. Tissue Eng 2006 2.53
4 Derivation and comparative assessment of retinal pigment epithelium from human embryonic stem cells using transcriptomics. Cloning Stem Cells 2004 2.32
5 Carbon nanotube applications for tissue engineering. Biomaterials 2006 2.25
6 Anterior urethral valves and diverticula in children: a result of ruptured Cowper's duct cyst? BJU Int 2004 2.19
7 The use of whole organ decellularization for the generation of a vascularized liver organoid. Hepatology 2011 2.09
8 Human amniotic fluid-derived stem cells are rejected after transplantation in the myocardium of normal, ischemic, immuno-suppressed or immuno-deficient rat. J Mol Cell Cardiol 2006 1.99
9 Generation of histocompatible tissues using nuclear transplantation. Nat Biotechnol 2002 1.97
10 Antiangiogenic properties of gold nanoparticles. Clin Cancer Res 2005 1.78
11 Controlled fabrication of a biological vascular substitute. Biomaterials 2005 1.76
12 Cell-seeded tubularized scaffolds for reconstruction of long urethral defects: a preclinical study. Eur Urol 2012 1.69
13 Tissue engineering, stem cells, and cloning: opportunities for regenerative medicine. J Am Soc Nephrol 2004 1.68
14 Implantation of autologous urine derived stem cells expressing vascular endothelial growth factor for potential use in genitourinary reconstruction. J Urol 2011 1.56
15 Decellularization methods of porcine kidneys for whole organ engineering using a high-throughput system. Biomaterials 2012 1.55
16 Urine derived cells are a potential source for urological tissue reconstruction. J Urol 2008 1.54
17 Bioengineered vascular access maintains structural integrity in response to arteriovenous flow and repeated needle puncture. J Vasc Surg 2012 1.52
18 The influence of electrospun aligned poly(epsilon-caprolactone)/collagen nanofiber meshes on the formation of self-aligned skeletal muscle myotubes. Biomaterials 2008 1.47
19 Whole organ decellularization - a tool for bioscaffold fabrication and organ bioengineering. Conf Proc IEEE Eng Med Biol Soc 2009 1.47
20 The in vivo stability of electrospun polycaprolactone-collagen scaffolds in vascular reconstruction. Biomaterials 2008 1.46
21 Human amniotic fluid stem cells can integrate and differentiate into epithelial lung lineages. Stem Cells 2008 1.46
22 Multipotential differentiation of human urine-derived stem cells: potential for therapeutic applications in urology. Stem Cells 2013 1.46
23 Engineered multilayer ovarian tissue that secretes sex steroids and peptide hormones in response to gonadotropins. Biomaterials 2012 1.45
24 Randomized comparative study between buccal mucosal and acellular bladder matrix grafts in complex anterior urethral strictures. J Urol 2008 1.45
25 Production and implantation of renal extracellular matrix scaffolds from porcine kidneys as a platform for renal bioengineering investigations. Ann Surg 2012 1.45
26 Protective effect of human amniotic fluid stem cells in an immunodeficient mouse model of acute tubular necrosis. PLoS One 2010 1.44
27 Chondrogenic differentiation of amniotic fluid-derived stem cells. J Mol Histol 2007 1.44
28 Principals of neovascularization for tissue engineering. Mol Aspects Med 2002 1.44
29 Reprogramming of human somatic cells using human and animal oocytes. Cloning Stem Cells 2009 1.40
30 Development of a composite vascular scaffolding system that withstands physiological vascular conditions. Biomaterials 2008 1.35
31 Hybrid printing of mechanically and biologically improved constructs for cartilage tissue engineering applications. Biofabrication 2012 1.34
32 Regenerative medicine as applied to solid organ transplantation: current status and future challenges. Transpl Int 2010 1.33
33 Stretch and growth: the molecular and physiologic influences of tissue expansion. Plast Reconstr Surg 2002 1.30
34 Human urine-derived stem cells seeded in a modified 3D porous small intestinal submucosa scaffold for urethral tissue engineering. Biomaterials 2010 1.30
35 Amniotic fluid and placental stem cells. Methods Enzymol 2006 1.30
36 Bilayered scaffold for engineering cellularized blood vessels. Biomaterials 2010 1.29
37 Amniotic fluid and bone marrow derived mesenchymal stem cells can be converted to smooth muscle cells in the cryo-injured rat bladder and prevent compensatory hypertrophy of surviving smooth muscle cells. J Urol 2007 1.28
38 Urethral stricture repair with an off-the-shelf collagen matrix. J Urol 2003 1.26
39 Mesenchymal stem cells and adipogenesis in hemangioma involution. Stem Cells 2006 1.25
40 Differentiation of human bone marrow mesenchymal stem cells into bladder cells: potential for urological tissue engineering. Tissue Eng Part A 2010 1.25
41 Oxygen generating scaffolds for enhancing engineered tissue survival. Biomaterials 2008 1.24
42 Identification and characterization of bioactive factors in bladder submucosa matrix. Biomaterials 2007 1.24
43 Urethral replacement using cell seeded tubularized collagen matrices. J Urol 2002 1.24
44 A rat decellularized small bowel scaffold that preserves villus-crypt architecture for intestinal regeneration. Biomaterials 2012 1.21
45 Characterization of urine-derived stem cells obtained from upper urinary tract for use in cell-based urological tissue engineering. Tissue Eng Part A 2011 1.21
46 Tissue-specific extracellular matrix coatings for the promotion of cell proliferation and maintenance of cell phenotype. Biomaterials 2009 1.21
47 Cell cycle checkpoint function in bladder cancer. J Natl Cancer Inst 2003 1.21
48 Complex heterogeneous tissue constructs containing multiple cell types prepared by inkjet printing technology. Biomaterials 2012 1.21
49 Tubularized urethral replacement with unseeded matrices: what is the maximum distance for normal tissue regeneration? World J Urol 2008 1.20
50 In vivo administration of vascular endothelial growth factor (VEGF) and its antagonist, soluble neuropilin-1, predicts a role of VEGF in the progression of acute myeloid leukemia in vivo. Blood 2002 1.19
51 Sources of stem cells for regenerative medicine. Stem Cell Rev 2008 1.17
52 Oxygen producing biomaterials for tissue regeneration. Biomaterials 2007 1.16
53 Myogenic differentiation of human bone marrow mesenchymal stem cells on a 3D nano fibrous scaffold for bladder tissue engineering. Biomaterials 2009 1.16
54 Regenerative medicine and organ transplantation: past, present, and future. Transplantation 2011 1.14
55 Testicular volume: comparison of orchidometer and US measurements in dogs. Radiology 2002 1.13
56 Human amniotic fluid stem cell preconditioning improves their regenerative potential. Stem Cells Dev 2011 1.12
57 In vitro evaluation of electrospun nanofiber scaffolds for vascular graft application. J Biomed Mater Res A 2007 1.12
58 Engineering functional bladder tissues. J Tissue Eng Regen Med 2012 1.10
59 Valproic acid confers functional pluripotency to human amniotic fluid stem cells in a transgene-free approach. Mol Ther 2012 1.10
60 Tissue-engineered conduit using urine-derived stem cells seeded bacterial cellulose polymer in urinary reconstruction and diversion. Biomaterials 2010 1.08
61 Tissue engineering, stem cells, cloning, and parthenogenesis: new paradigms for therapy. J Exp Clin Assist Reprod 2004 1.08
62 Engineering of blood vessels from acellular collagen matrices coated with human endothelial cells. Tissue Eng 2006 1.07
63 Endostatin inhibits the vascular endothelial growth factor-induced mobilization of endothelial progenitor cells. Cancer Res 2003 1.06
64 Propagation, expansion, and multilineage differentiation of human somatic stem cells from dermal progenitors. Stem Cells Dev 2005 1.05
65 Cyclic mechanical preconditioning improves engineered muscle contraction. Tissue Eng Part A 2008 1.04
66 Tissue engineering a complete vaginal replacement from a small biopsy of autologous tissue. Transplantation 2008 1.04
67 A novel use of centrifugal force for cell seeding into porous scaffolds. Biomaterials 2004 1.04
68 Stem cells derived from amniotic fluid: new potentials in regenerative medicine. Reprod Biomed Online 2009 1.03
69 Three-dimensional culture of hepatocytes on porcine liver tissue-derived extracellular matrix. Biomaterials 2011 1.02
70 Optimization of human skeletal muscle precursor cell culture and myofiber formation in vitro. Methods 2008 1.02
71 Skeletal myogenic differentiation of urine-derived stem cells and angiogenesis using microbeads loaded with growth factors. Biomaterials 2012 1.00
72 Will regenerative medicine replace transplantation? Cold Spring Harb Perspect Med 2013 1.00
73 Osteogenic differentiation of human amniotic fluid-derived stem cells induced by bone morphogenetic protein-7 and enhanced by nanofibrous scaffolds. Biomaterials 2009 1.00
74 Self-renewal and differentiation capacity of urine-derived stem cells after urine preservation for 24 hours. PLoS One 2013 0.99
75 Formation of corporal tissue architecture in vivo using human cavernosal muscle and endothelial cells seeded on collagen matrices. Tissue Eng 2003 0.99
76 Bioprinted amniotic fluid-derived stem cells accelerate healing of large skin wounds. Stem Cells Transl Med 2012 0.98
77 Cell and organ bioengineering technology as applied to gastrointestinal diseases. Gut 2012 0.98
78 Optimization of a natural collagen scaffold to aid cell-matrix penetration for urologic tissue engineering. Biomaterials 2009 0.98
79 In vitro generation of three-dimensional renal structures. Methods 2008 0.97
80 High transduction efficiency of human amniotic fluid stem cells mediated by adenovirus vectors. Stem Cells Dev 2008 0.97
81 In-vitro reconstitution of three-dimensional human salivary gland tissue structures. Differentiation 2007 0.97
82 Stem cell sources to treat diabetes. J Cell Biochem 2009 0.97
83 Tissue engineering: current strategies and future directions. Chonnam Med J 2011 0.96
84 Lack of major involvement of human uroplakin genes in vesicoureteral reflux: implications for disease heterogeneity. Kidney Int 2004 0.96
85 Posterior urethral valves. ScientificWorldJournal 2009 0.96
86 Phenotypic and functional characterization of in vivo tissue engineered smooth muscle from normal and pathological bladders. J Urol 2002 0.96
87 In vitro biocompatibility evaluation of naturally derived and synthetic biomaterials using normal human bladder smooth muscle cells. J Urol 2002 0.96
88 A liver-on-a-chip platform with bioprinted hepatic spheroids. Biofabrication 2016 0.96
89 In vitro cardiomyogenic potential of human amniotic fluid stem cells. J Tissue Eng Regen Med 2011 0.95
90 Co-electrospun dual scaffolding system with potential for muscle-tendon junction tissue engineering. Biomaterials 2010 0.95
91 Reconstitution of human corpus cavernosum smooth muscle in vitro and in vivo. Tissue Eng 2002 0.95
92 The use of thermal treatments to enhance the mechanical properties of electrospun poly(epsilon-caprolactone) scaffolds. Biomaterials 2007 0.95
93 Human amniotic fluid stem cell injection therapy for urethral sphincter regeneration in an animal model. BMC Med 2012 0.94
94 Correction of diabetic erectile dysfunction with adipose derived stem cells modified with the vascular endothelial growth factor gene in a rodent diabetic model. PLoS One 2013 0.94
95 The use of keratin biomaterials derived from human hair for the promotion of rapid regeneration of peripheral nerves. Biomaterials 2007 0.94
96 Porcine pancreas extracellular matrix as a platform for endocrine pancreas bioengineering. Biomaterials 2013 0.94
97 Engineered cartilage covered ear implants for auricular cartilage reconstruction. Biomacromolecules 2010 0.94
98 Amniotic fluid stem cells improve survival and enhance repair of damaged intestine in necrotising enterocolitis via a COX-2 dependent mechanism. Gut 2013 0.94
99 Autologous penile corpora cavernosa replacement using tissue engineering techniques. J Urol 2002 0.94
100 Peripheral nerve regeneration using acellular nerve grafts. J Biomed Mater Res A 2004 0.94
101 Stem cells in urology. Nat Clin Pract Urol 2008 0.94
102 Regenerative medicine strategies for treating neurogenic bladder. Int Neurourol J 2011 0.93
103 Amniotic fluid-derived stem cells in regenerative medicine research. Arch Pharm Res 2012 0.93
104 The effect of urine-derived stem cells expressing VEGF loaded in collagen hydrogels on myogenesis and innervation following after subcutaneous implantation in nude mice. Biomaterials 2013 0.93
105 Stem cells: cross-talk and developmental programs. Philos Trans R Soc Lond B Biol Sci 2004 0.93
106 Evaluation of hydrogels for bio-printing applications. J Biomed Mater Res A 2012 0.93
107 Bioreactor maintained living skin matrix. Tissue Eng Part A 2009 0.93
108 Amniotic fluid and placental membranes: unexpected sources of highly multipotent cells. Semin Reprod Med 2013 0.93
109 Regenerative medicine as applied to general surgery. Ann Surg 2012 0.92
110 GeneChip analysis of human embryonic stem cell differentiation into hemangioblasts: an in silico dissection of mixed phenotypes. Genome Biol 2007 0.92
111 Angiogenic gene-modified muscle cells for enhancement of tissue formation. Tissue Eng 2005 0.92
112 Testicular tissue cryopreservation and spermatogonial stem cell transplantation to restore fertility: from bench to bedside. Stem Cell Res Ther 2014 0.92
113 The regeneration process of the striated urethral sphincter involves activation of intrinsic satellite cells. Anat Embryol (Berl) 2003 0.92
114 Smart biomaterials design for tissue engineering and regenerative medicine. Biomaterials 2007 0.91
115 In vivo evaluation of acellular human dermis for abdominal wall repair. J Biomed Mater Res A 2010 0.91
116 Bioengineered self-seeding heart valves. J Thorac Cardiovasc Surg 2011 0.91
117 Pancreatic tumor growth is regulated by the balance between positive and negative modulators of angiogenesis. Angiogenesis 2002 0.91
118 The effect of controlled release of PDGF-BB from heparin-conjugated electrospun PCL/gelatin scaffolds on cellular bioactivity and infiltration. Biomaterials 2012 0.91
119 The clinician scientist and medical advances. J Urol 2008 0.91
120 Biomaterials for integration with 3-D bioprinting. Ann Biomed Eng 2014 0.90
121 Bladder acellular matrix and its application in bladder augmentation. Tissue Eng Part B Rev 2013 0.90
122 Preservation of micro-architecture and angiogenic potential in a pulmonary acellular matrix obtained using intermittent intra-tracheal flow of detergent enzymatic treatment. Biomaterials 2013 0.90
123 Vascular therapy for radiation cystitis. Neurourol Urodyn 2010 0.90
124 Restoration of functional motor units in a rat model of sphincter injury by muscle precursor cell autografts. Transplantation 2003 0.90
125 Spatial and temporal control of transgene expression through ultrasound-mediated induction of the heat shock protein 70B promoter in vivo. Hum Gene Ther 2002 0.89
126 Tissue engineering using adult stem cells. Methods Enzymol 2006 0.89
127 Tissue specific synthetic ECM hydrogels for 3-D in vitro maintenance of hepatocyte function. Biomaterials 2012 0.89
128 Scaffold technologies for controlling cell behavior in tissue engineering. Biomed Mater 2013 0.89
129 MYC gene delivery to adult mouse utricles stimulates proliferation of postmitotic supporting cells in vitro. PLoS One 2012 0.88
130 Combined systemic and local delivery of stem cell inducing/recruiting factors for in situ tissue regeneration. FASEB J 2011 0.88
131 Cell therapy with human renal cell cultures containing erythropoietin-positive cells improves chronic kidney injury. Stem Cells Transl Med 2012 0.88
132 Inkjet-mediated gene transfection into living cells combined with targeted delivery. Tissue Eng Part A 2009 0.88
133 Airway tissue engineering. Expert Opin Biol Ther 2011 0.88
134 In situ tissue regeneration through host stem cell recruitment. Exp Mol Med 2013 0.87
135 Early outcome following complete primary repair of bladder exstrophy in the newborn. J Urol 2005 0.87
136 Bioengineered corporal tissue for structural and functional restoration of the penis. Proc Natl Acad Sci U S A 2009 0.87
137 Airway tissue engineering: an update. Expert Opin Biol Ther 2014 0.87
138 Local and systemic effects of a tissue engineered neobladder in a canine cystoplasty model. J Urol 2008 0.87
139 Urothelial cell culture: stratified urothelial sheet and three-dimensional growth of urothelial structure. Methods Mol Biol 2013 0.86
140 Renal bioengineering with scaffolds generated from human kidneys. Nephron Exp Nephrol 2014 0.86
141 Human amnion epithelial cells induced to express functional cystic fibrosis transmembrane conductance regulator. PLoS One 2012 0.86
142 Peripheral nerve regeneration using a keratin-based scaffold: long-term functional and histological outcomes in a mouse model. J Hand Surg Am 2008 0.86
143 Mesenchymal stem cells: emerging therapy for Duchenne muscular dystrophy. PM R 2009 0.86
144 Organ engineering--combining stem cells, biomaterials, and bioreactors to produce bioengineered organs for transplantation. Bioessays 2012 0.86
145 Muscle precursor cells for the restoration of irreversibly damaged sphincter function. Cell Transplant 2012 0.86
146 In vitro evaluation of a poly(lactide-co-glycolide)-collagen composite scaffold for bone regeneration. Biomaterials 2006 0.86
147 Proximal hypospadias. Urol Clin North Am 2002 0.85
148 Megaureter. ScientificWorldJournal 2010 0.85
149 Cavernous nerve regeneration using acellular nerve grafts. World J Urol 2008 0.85
150 Complications of hypospadias repair. Urol Clin North Am 2002 0.85
151 Functional recovery of completely denervated muscle: implications for innervation of tissue-engineered muscle. Tissue Eng Part A 2012 0.85
152 Testicular hypotrophy does not correlate with grade of adolescent varicocele. J Urol 2005 0.85
153 Parthenogenesis-derived multipotent stem cells adapted for tissue engineering applications. Methods 2008 0.85
154 Composite scaffolds for the engineering of hollow organs and tissues. Methods 2008 0.85
155 Microencapsulation of Leydig cells: a system for testosterone supplementation. Endocrinology 2003 0.85
156 A keratin biomaterial gel hemostat derived from human hair: evaluation in a rabbit model of lethal liver injury. J Biomed Mater Res B Appl Biomater 2009 0.85
157 Injection of autologous muscle stem cells (myoblasts) for the treatment of vocal fold paralysis: a pilot study. Laryngoscope 2007 0.84
158 Amniotic fluid-derived stem cells as a cell source for bone tissue engineering. Tissue Eng Part A 2012 0.84
159 Cell microencapsulation. Adv Exp Med Biol 2010 0.84
160 Penile urethra replacement with autologous cell-seeded tubularized collagen matrices. J Tissue Eng Regen Med 2012 0.84
161 Microarray analysis of bladder smooth muscle from patients with myelomeningocele. BJU Int 2008 0.84
162 Robotic assisted ureteral reimplantation: current status. Curr Urol Rep 2013 0.84
163 Angiogenic gene modification of skeletal muscle cells to compensate for ageing-induced decline in bioengineered functional muscle tissue. BJU Int 2008 0.84
164 The effect of differentiation stage of amniotic fluid stem cells on bone regeneration. Biomaterials 2012 0.83
165 In vitro reconstitution of human kidney structures for renal cell therapy. Nephrol Dial Transplant 2012 0.83
166 Non-invasive longitudinal tracking of human amniotic fluid stem cells in the mouse heart. Stem Cells Dev 2008 0.83
167 Cryopreservation of amniotic fluid-derived stem cells using natural cryoprotectants and low concentrations of dimethylsulfoxide. Cryobiology 2011 0.83
168 Isolation of c-Kit+ human amniotic fluid stem cells from second trimester. Methods Mol Biol 2013 0.83
169 Engineering of vaginal tissue in vivo. Tissue Eng 2003 0.83
170 The effect of in vitro formation of acetylcholine receptor (AChR) clusters in engineered muscle fibers on subsequent innervation of constructs in vivo. Biomaterials 2013 0.83
171 Repair of peripheral nerve defects in rabbits using keratin hydrogel scaffolds. Tissue Eng Part A 2011 0.83
172 Tissue engineering of the penis. ScientificWorldJournal 2011 0.83
173 A canine model of irreversible urethral sphincter insufficiency. BJU Int 2008 0.82
174 A method to improve cellular content for corporal tissue engineering. Tissue Eng Part A 2008 0.82
175 End-to-side neurorrhaphy using an electrospun PCL/collagen nerve conduit for complex peripheral motor nerve regeneration. Biomaterials 2012 0.82
176 Pdx1 and controlled culture conditions induced differentiation of human amniotic fluid-derived stem cells to insulin-producing clusters. J Tissue Eng Regen Med 2012 0.82
177 Erythropoietin producing cells for potential cell therapy. World J Urol 2008 0.82
178 Ischemia/reperfusion-induced renal failure in rats as a model for evaluating cell therapies. Ren Fail 2012 0.82
179 Bioreactors for development of tissue engineered heart valves. Ann Biomed Eng 2010 0.81
180 Controllable dual protein delivery through electrospun fibrous scaffolds with different hydrophilicities. Biomed Mater 2013 0.81
181 A collagen matrix derived from bladder can be used to engineer smooth muscle tissue. World J Urol 2008 0.81
182 Bilayered constructs aimed at osteochondral strategies: the influence of medium supplements in the osteogenic and chondrogenic differentiation of amniotic fluid-derived stem cells. Acta Biomater 2012 0.81
183 Therapeutic cloning and tissue engineering. Curr Top Dev Biol 2004 0.81
184 Genetic modification of primate amniotic fluid-derived stem cells produces pancreatic progenitor cells in vitro. Cells Tissues Organs 2013 0.81
185 Tissue engineering of functional salivary gland tissue. Laryngoscope 2005 0.81
186 In vitro osteogenic differentiation of human amniotic fluid-derived stem cells on a poly(lactide-co-glycolide) (PLGA)-bladder submucosa matrix (BSM) composite scaffold for bone tissue engineering. Biomed Mater 2013 0.81
187 Tumor cell-associated neuropilin-1 and vascular endothelial growth factor expression as determinants of tumor growth in neuroblastoma. Neuropathology 2005 0.81
188 Magnetic resonance imaging of pelvic musculoskeletal and genitourinary anatomy in patients before and after complete primary repair of bladder exstrophy. J Urol 2005 0.81
189 Diaphragmatic muscle reconstruction with an aligned electrospun poly(ε-caprolactone)/collagen hybrid scaffold. Biomaterials 2013 0.80
190 Regenerative medicine strategies for treatment of neurogenic bladder. Therapy 2009 0.80
191 A 3D bioprinted complex structure for engineering the muscle-tendon unit. Biofabrication 2015 0.80
192 The effect of epigenetic therapy on congenital neurogenic bladders--a pilot study. Urology 2010 0.80
193 Endoscopic treatment of vesicoureteral reflux with autologous chondrocytes: postoperative sonographic features. Radiology 2004 0.80
194 Auricular reconstruction using tissue-engineered alloplastic implants for improved clinical outcomes. Plast Reconstr Surg 2014 0.79
195 Substrate elasticity controls cell proliferation, surface marker expression and motile phenotype in amniotic fluid-derived stem cells. J Mech Behav Biomed Mater 2012 0.79
196 Host cell mobilization for in situ tissue regeneration. Rejuvenation Res 2008 0.79
197 Endothelialization of heart valve matrix using a computer-assisted pulsatile bioreactor. Tissue Eng Part A 2009 0.79
198 Whole kidney engineering for clinical translation. Curr Opin Organ Transplant 2015 0.79
199 Tissue engineered testicular prostheses with prolonged testosterone release. World J Urol 2008 0.78
200 Advent and maturation of regenerative medicine. Curr Stem Cell Res Ther 2012 0.78
201 Tissue engineering in urethral reconstruction. Arch Esp Urol 2014 0.78
202 Wound Healing Versus Regeneration: Role of the Tissue Environment in Regenerative Medicine. MRS Bull 2010 0.78
203 Therapeutic cloning applications for organ transplantation. Transpl Immunol 2004 0.78
204 Editorial: effective bio-economic approaches for stem cell therapy and regenerative medicine. Curr Stem Cell Res Ther 2012 0.78
205 Halofuginone-coated urethral catheters prevent periurethral spongiofibrosis in a rat model of urethral injury. J Endourol 2011 0.78
206 GeneChips in stem cell research. Methods Enzymol 2006 0.78
207 In vitro systems for tissue engineering. Ann N Y Acad Sci 2002 0.78
208 Syngeneic Myoblast Transplantation Improves Muscle Function in a Murine Model of X-Linked Myotubular Myopathy. Cell Transplant 2014 0.78
209 Re: Orthotopic grafting of cryopreserved prepubertal testicular tissue: in search of a simple yet effective cryopreservation protocol. J Urol 2012 0.77
210 Failure of differentiation into mature myotubes by muscle precursor cells with the side-population phenotype after injection into irreversibly damaged striated urethral sphincter. Transplantation 2005 0.77
211 Re: Long non-coding RNA H19 increases bladder cancer metastasis by associating with EZH2 and inhibiting E-cadherin expression. J Urol 2013 0.77
212 Calcification after myocardial infarction is independent of amniotic fluid stem cell injection. Cardiovasc Pathol 2010 0.77
213 Re: Inhibition of Ca2+ -activated Cl- channel ANO1/TMEM16A expression suppresses tumor growth and invasiveness in human prostate carcinoma. J Urol 2013 0.77
214 An emerging cell-based strategy in orthopaedics: endothelial progenitor cells. Knee Surg Sports Traumatol Arthrosc 2012 0.77
215 Re: Ion Channel TRPM8 Promotes Hypoxic Growth of Prostate Cancer Cells via an O2-Independent and RACK1-Mediated Mechanism of HIF-1α Stabilization. J Urol 2015 0.77
216 Rate and predictors of spontaneous resolution of prenatally diagnosed primary nonrefluxing megaureter. J Urol 2002 0.77
217 One and four layer acellular bladder matrix for fascial tissue reconstruction. J Mater Sci Mater Med 2011 0.77
218 Engineering of human cartilage rods: potential application for penile prostheses. J Urol 2002 0.77
219 Efficient recovery of endothelial progenitors for clinical translation. Tissue Eng Part C Methods 2009 0.77
220 Directed apoptosis in Cox-2-overexpressing cancer cells through expression-targeted gene delivery. Gene Ther 2003 0.77
221 In vitro and in vivo characterization of a novel liposomal butorphanol formulation for treatment of pruritus. Acta Derm Venereol 2008 0.77
222 Prospects for engineering the urinary tract. Nephron Exp Nephrol 2004 0.77
223 Functional genomics: new insights into the 'function' of low levels of gene expression in stem cells. Curr Genomics 2010 0.77
224 Bioengineering a vaginal replacement using a small biopsy of autologous tissue. Semin Reprod Med 2011 0.77
225 Is adolescent varicocele a progressive disease process? J Urol 2004 0.77
226 Producing organs in the laboratory. Curr Urol Rep 2008 0.76
227 Re: Microvesicles released from human renal cancer stem cells stimulate angiogenesis and formation of lung premetastatic niche. J Urol 2012 0.76
228 Safeguarding pluripotent stem cells for cell therapy with a non-viral, non-integrating episomal suicide construct. Biomaterials 2012 0.76
229 Ethanol alters the osteogenic differentiation of amniotic fluid-derived stem cells. Alcohol Clin Exp Res 2010 0.76
230 Re: Expression and Localization of a UT-B Urea Transporter in the Human Bladder. J Urol 2015 0.76
231 The future of bladder research: molecular profiling, new drug targets, gene therapy, and tissue engineering. Curr Urol Rep 2007 0.76
232 Downregulation of metabolic activity increases cell survival under hypoxic conditions: potential applications for tissue engineering. Tissue Eng Part A 2014 0.76
233 Urothelial cell culture. Methods Mol Biol 2013 0.76
234 A system for the enhancement of adenovirus mediated gene transfer to uro-epithelium. J Urol 2002 0.76
235 Re: Innervation of Reconstructed Bladder Above the Level of Spinal Cord Injury for Inducing Micturition by Contractions of the Abdomen-to-Bladder Reflex Arc. J Urol 2011 0.76
236 Cell therapy for cystic fibrosis. J Tissue Eng Regen Med 2013 0.76
237 Autologously generated tissue-engineered bone flaps for reconstruction of large mandibular defects in an ovine model. Tissue Eng Part A 2015 0.76
238 Bladder growth and development after complete primary repair of bladder exstrophy in the newborn with comparison to staged approach. J Urol 2005 0.76
239 Re: a gene signature identified using a mouse model of androgen receptor-dependent prostate cancer predicts biochemical relapse in human disease. J Urol 2013 0.75
240 Re: Targeting PIM kinase enhances the activity of sunitinib in renal cell carcinoma. J Urol 2012 0.75
241 Re: tumor radiation response enhancement by acoustical stimulation of the vasculature. J Urol 2013 0.75
242 Re: effectiveness of a combination therapy using calcineurin inhibitor and mTOR inhibitor in preventing allograft rejection and post-transplantation renal cancer progression. J Urol 2012 0.75
243 Re: a novel imaging approach for early detection of prostate cancer based on endogenous zinc sensing. J Urol 2011 0.75
244 Re: Mutations in TERT Promoter and FGFR3 and Telomere Length in Bladder Cancer. J Urol 2016 0.75
245 Re: Three-dimensional cancer-bone metastasis model using ex-vivo co-cultures of live calvarial bones and cancer cells. J Urol 2012 0.75
246 Re: The long noncoding RNA SChLAP1 promotes aggressive prostate cancer and antagonizes the SWI/SNF complex. J Urol 2014 0.75
247 Re: Expression of Nuclear Matrix Proteins Binding Matrix Attachment Regions in Prostate Cancer. PARP-1: New Player in Tumor Progression. J Urol 2015 0.75
248 Re: overexpression of androgen receptor enhances the binding of the receptor to the chromatin in prostate cancer. J Urol 2012 0.75
249 Re: Dietary sources of N-nitroso compounds and bladder cancer risk: findings from the Los Angeles Bladder Cancer Study. J Urol 2014 0.75
250 Re: JNK and PTEN cooperatively control the development of invasive adenocarcinoma of the prostate. J Urol 2013 0.75
251 Re: TP53INP1 as new therapeutic target in castration-resistant prostate cancer. J Urol 2013 0.75
252 Re: Nkx3.1 and myc crossregulate shared target genes in mouse and human prostate tumorigenesis. J Urol 2012 0.75
253 Re: antitumoral effects of vasoactive intestinal peptide in human renal cell carcinoma xenografts in athymic nude mice. J Urol 2013 0.75
254 Re: Pretargeted dual-modality immuno-SPECT and near-infrared fluorescence imaging for image-guided surgery of prostate cancer. J Urol 2015 0.75
255 Re: Lin28 sustains early renal progenitors and induces Wilms tumor. J Urol 2014 0.75
256 Re: Circulating tumor cells exhibit a biologically aggressive cancer phenotype accompanied by selective resistance to chemotherapy. J Urol 2015 0.75
257 Microarray analysis of exstrophic human bladder smooth muscle. BJU Int 2007 0.75
258 Re: decreased androgen receptor expression may contribute to spermatogenesis failure in rats exposed to low concentration of bisphenol A. J Urol 2013 0.75
259 Re: GPRC6A regulates prostate cancer progression. J Urol 2012 0.75
260 Re: glucocorticoid mediates water avoidance stress-sensitized colon-bladder cross-talk via RSK2/PSD-95/NR2B in rats. J Urol 2013 0.75
261 Re: SCRIB expression is deregulated in human prostate cancer, and its deficiency in mice promotes prostate neoplasia. J Urol 2012 0.75
262 Re: Peroxiredoxin 4: A Novel Secreted Mediator of Cancer Induced Osteoclastogenesis. J Urol 2015 0.75
263 Re: IGFBP-3 is a metastasis suppression gene in prostate cancer. J Urol 2012 0.75
264 Re: a new experimental rat model of erectile dysfunction and lower urinary tract symptoms associated with benign prostatic hyperplasia: the testosterone-supplemented spontaneously hypertensive rat. J Urol 2013 0.75
265 Re: DMRT1 prevents female reprogramming in the postnatal mammalian testis. J Urol 2012 0.75
266 Re: Imbalanced Lipid Homeostasis in the Conditional Dicer1 Knockout Mouse Epididymis Causes Instability of the Sperm Membrane. J Urol 2015 0.75
267 Re: Cancer cells promote survival through depletion of the von Hippel-Lindau tumor suppressor by protein crosslinking. J Urol 2012 0.75
268 Re: L-type calcium channel modulates cystic kidney phenotype. J Urol 2015 0.75
269 Re: CSF1R signaling blockade stanches tumor-infiltrating myeloid cells and improves the efficacy of radiotherapy in prostate cancer. J Urol 2013 0.75
270 Re: Nanoencapsulated anti-CK2 small molecule drug or siRNA specifically targets malignant cancer but not benign cells. J Urol 2012 0.75
271 Re: Down-regulation of CatSper1 channel in epididymal spermatozoa contributes to the pathogenesis of asthenozoospermia, whereas up-regulation of the Channel by Sheng-Jing-San treatment improves the sperm motility of asthenozoospermia in rats. J Urol 2013 0.75
272 Re: High-fat diet activates pro-inflammatory response in the prostate through association of Stat-3 and NF-κB. J Urol 2012 0.75
273 Re: Inactivation of androgen-induced regulator ARD1 inhibits androgen receptor acetylation and prostate tumorigenesis. J Urol 2012 0.75
274 Re: basigin null mutant male mice are sterile and exhibit impaired interactions between germ cells and Sertoli cells. J Urol 2014 0.75
275 Re: Bone Marrow-Derived Cells Contribute to Regeneration of Injured Prostate Epithelium and Stroma. J Urol 2015 0.75
276 Re: epigenetic regulation of phosphatidylinositol 3,4,5-triphosphate-dependent Rac exchanger 1 gene expression in prostate cancer cells. J Urol 2012 0.75
277 Re: A Human Prostatic Bacterial Isolate Alters the Prostatic Microenvironment and Accelerates Prostate Cancer Progression. J Urol 2015 0.75
278 Re: Aire-dependent thymic development of tumor-associated regulatory T cells. J Urol 2013 0.75
279 Re: Uric acid stones in the urinary bladder of aryl hydrocarbon receptor (AhR) knockout mice. J Urol 2012 0.75
280 Re: Androgen receptor and microRNA-21 axis downregulates transforming growth factor beta receptor II (TGFBR2) expression in prostate cancer. J Urol 2015 0.75
281 Re: eIF4E Phosphorylation Promotes Tumorigenesis and is Associated With Prostate Cancer Progression. J Urol 2011 0.75
282 Re: Haem oxygenase is synthetically lethal with the tumour suppressor fumarate hydratase. J Urol 2012 0.75
283 Re: synapse-directed delivery of immunomodulators using T-cell-conjugated nanoparticles. J Urol 2013 0.75
284 Re: Prostate cancer targeting motifs: expression of αν β3, neurotensin receptor 1, prostate specific membrane antigen, and prostate stem cell antigen in human prostate cancer cell lines and xenografts. J Urol 2012 0.75
285 Re: Protease nexin 1 inhibits hedgehog signaling in prostate adenocarcinoma. J Urol 2013 0.75
286 Re: Discovery and Characterization of Small Molecules that Target the GTPase Ral. J Urol 2015 0.75
287 CD133 antibody conjugation to decellularized human heart valves intended for circulating cell capture. Biomed Mater 2015 0.75
288 Re: Estrogen receptor β upregulates FOXO3a and causes induction of apoptosis through PUMA in prostate cancer. J Urol 2015 0.75
289 Re: cancer stem-like cells contribute to Cisplatin resistance and progression in bladder cancer. J Urol 2012 0.75
290 Re: enhanced susceptibility to urinary tract infection in the spinal cord-injured host with neurogenic bladder. J Urol 2014 0.75
291 Re: miR-28-5p promotes chromosomal instability in VHL-associated cancers by inhibiting Mad2 translation. J Urol 2014 0.75
292 Re: Developmental control of apoptosis by the immunophilin aryl hydrocarbon receptor-interacting protein (AIP) involves mitochondrial import of the survivin protein. J Urol 2011 0.75
293 Re: Shrinkage of experimental benign prostatic hyperplasia and reduction of prostatic cell volume by a gastrin-releasing peptide antagonist. J Urol 2013 0.75
294 Re: Circulating Biomarkers of One-Carbon Metabolism in Relation to Renal Cell Carcinoma Incidence and Survival. J Urol 2015 0.75
295 Re: prevention of maternal aging-associated oocyte aneuploidy and meiotic spindle defects in mice by dietary and genetic strategies. J Urol 2012 0.75
296 Re: Intravesical TRPV4 blockade reduces repeated variate stress-induced bladder dysfunction by increasing bladder capacity and decreasing voiding frequency in male rats. J Urol 2014 0.75
297 Re: the E3 ubiquitin ligase Cullin 4A regulates meiotic progression in mouse spermatogenesis. J Urol 2012 0.75
298 Re: activation of HIF2α in kidney proximal tubule cells causes abnormal glycogen deposition but not tumorigenesis. J Urol 2013 0.75
299 Re: Adipose tissue-derived stem cells suppress acute cellular rejection by TSG-6 and CD44 interaction in rat kidney transplantation. J Urol 2015 0.75
300 Re: fkbp52 regulates androgen receptor transactivation activity and male urethra morphogenesis. J Urol 2011 0.75
301 Re: early life inorganic lead exposure induces testicular teratoma and renal and urinary bladder preneoplasia in adult metallothionein-knockout mice but not in wild type mice. J Urol 2011 0.75
302 Re: PIK3CA mutation spectrum in urothelial carcinoma reflects cell context-dependent signaling and phenotypic outputs. J Urol 2013 0.75
303 Re: Sexual selection by female immunity against paternal antigens can fix loss of function alleles. J Urol 2012 0.75
304 Re: lncRNA-dependent mechanisms of androgen-receptor-regulated gene activation programs. J Urol 2014 0.75
305 Re: licensing of gametogenesis, dependent on RNA binding protein DAZL, as a gateway to sexual differentiation of fetal germ cells. J Urol 2011 0.75
306 Uro-science. J Urol 2010 0.75
307 Re: Sex Hormone-Dependent tRNA Halves Enhance Cell Proliferation in Breast and Prostate Cancers. J Urol 2016 0.75
308 Re: Ca(2+)/calmodulin-dependent protein kinase II is associated with pelvic pain of neurogenic cystitis. J Urol 2012 0.75
309 Re: Generation of a mouse model of Von Hippel-Lindau kidney disease leading to renal cancers by expression of a constitutively active mutant of HIF1α. J Urol 2012 0.75
310 Re: Role of autonomous androgen receptor signaling in prostate cancer initiation is dichotomous and depends on the oncogenic signal. J Urol 2011 0.75
311 Re: Elf5 Inhibits TGF-β-Driven Epithelial-Mesenchymal Transition in Prostate Cancer by Repressing SMAD3 Activation. J Urol 2015 0.75
312 Re: An epirubicin-conjugated nanocarrier with MRI function to overcome lethal multidrug-resistant bladder cancer. J Urol 2012 0.75
313 Re: Lack of testicular seipin causes teratozoospermia syndrome in men. J Urol 2014 0.75
314 Re: Sall1 Maintains Nephron Progenitors and Nascent Nephrons by Acting as Both an Activator and a Repressor. J Urol 2015 0.75
315 Re: A unifying model for mTORC1-mediated regulation of mRNA translation. J Urol 2012 0.75
316 Re: expression and function of transforming growth factor-β isoforms and cognate receptors in the rat urinary bladder following cyclophosphamide-induced cystitis. J Urol 2014 0.75
317 Re: Bone-Induced c-Kit Expression in Prostate Cancer: A Driver of Intraosseous Tumor Growth. J Urol 2015 0.75
318 Re: mTORC1 Drives HIF-1α and VEGF-A Signalling via Multiple Mechanisms Involving 4E-BP1, S6K1 and STAT3. J Urol 2015 0.75
319 Re: Carvedilol efficiently protects kidneys without affecting the antitumor efficacy of cisplatin in mice. J Urol 2014 0.75
320 Re: Inhibition of neurotensin receptor 1 selectively sensitizes prostate cancer to ionizing radiation. J Urol 2012 0.75
321 Re: PLCε Knockdown Inhibits Prostate Cancer Cell Proliferation via Suppression of Notch Signalling and Nuclear Translocation of the Androgen Receptor. J Urol 2015 0.75
322 Re: the renin-angiotensin system plays a major role in voiding dysfunction of ovariectomized rats. J Urol 2014 0.75
323 A randomized, double-blind, placebo-controlled trial of anticholinergic medication for nonresponders to desmopressin for monosymptomatic nocturnal enuresis. Curr Urol Rep 2011 0.75
324 Re: Regulation of the ITGA2 Gene by Epigenetic Mechanisms in Prostate Cancer. J Urol 2015 0.75
325 Re: Loss of Expression of the Tumour Suppressor Gene AIMP3 Predicts Survival following Radiotherapy in Muscle-Invasive Bladder Cancer. J Urol 2015 0.75
326 Re: Prostate Sphere-Forming Stem Cells are Derived from the P63-Expressing Basal Compartment. J Urol 2015 0.75
327 Re: Chronic Oxidative Stress Leads to Malignant Transformation Along with Acquisition of Stem Cell Characteristics, and Epithelial to Mesenchymal Transition in Human Renal Epithelial Cells. J Urol 2015 0.75
328 Re: Differential transformation capacity of Src family kinases during the initiation of prostate cancer. J Urol 2011 0.75
329 Re: enhanced therapeutic effect of cisplatin on the prostate cancer in tumor-bearing mice by transfecting the attenuated salmonella carrying a plasmid co-expressing p53 gene and MDM2 siRNA. J Urol 2013 0.75
330 Re: Neurosensory perception of environmental cues modulates sperm motility critical for fertilization. J Urol 2014 0.75
331 Re: therapeutic potential of human mesenchymal stem cells producing IL-12 in a mouse xenograft model of renal cell carcinoma. J Urol 2011 0.75
332 Re: The cancer/testis antigen prostate-associated gene 4 (PAGE4) is a highly intrinsically disordered protein. J Urol 2011 0.75
333 Re: Cells of renin lineage take on a podocyte phenotype in aging nephropathy. J Urol 2014 0.75
334 Re: Mutations in 3'-long terminal repeat of HERV-W family in chromosome 7 upregulate syncytin-1 expression in urothelial cell carcinoma of the bladder through interacting with c-Myb. J Urol 2014 0.75
335 Re: PC3 is a cell line characteristic of prostatic small cell carcinoma. J Urol 2012 0.75
336 Re: RNA-Seq of Single Prostate CTCs Implicates Noncanonical Wnt Signaling in Antiandrogen Resistance. J Urol 2016 0.75
337 Re: Downregulation of Ral GTPase-activating protein promotes tumor invasion and metastasis of bladder cancer. J Urol 2013 0.75
338 Re: Understanding the pharmacological properties of a metabolic PET tracer in prostate cancer. J Urol 2014 0.75
339 Re: MicroRNA-449a acts as a tumor suppressor in human bladder cancer through the regulation of pocket proteins. J Urol 2012 0.75
340 Re: Tumour-Suppressive MicroRNA-29s Directly Regulate LOXL2 Expression and Inhibit Cancer Cell Migration and Invasion in Renal Cell Carcinoma. J Urol 2016 0.75
341 Re: reconstitution of experimental neurogenic bladder dysfunction using skeletal muscle-derived multipotent stem cells. J Urol 2011 0.75
342 Re: TERT Promoter Mutations and Telomerase Reactivation in Urothelial Cancer. J Urol 2015 0.75
343 Re: Cell Adhesion. Mechanical Strain Induces E-Cadherin-Dependent Yap1 and β-Catenin Activation to Drive Cell Cycle Entry. J Urol 2015 0.75
344 Re: NMR-based metabolomics study of canine bladder cancer. J Urol 2013 0.75
345 Re: Tumour-infiltrating Gr-1+ myeloid cells antagonize senescence in cancer. J Urol 2015 0.75
346 Re: a functional analysis of the influence of β3-adrenoceptors on the rat micturition cycle. J Urol 2014 0.75
347 Re: Both osteopontin-c and osteopontin-b splicing isoforms exert pro-tumorigenic roles in prostate cancer cells. J Urol 2013 0.75
348 Re: β-catenin is essential for Müllerian duct regression during male sexual differentiation. J Urol 2011 0.75
349 Re: Identification and characterization of membrane androgen receptors in the ZIP9 zinc transporter subfamily: II. Role of human ZIP9 in testosterone-induced prostate and breast cancer cell apoptosis. J Urol 2015 0.75
350 Re: Ligand-dependent corepressor acts as a novel androgen receptor corepressor, inhibits prostate cancer growth, and is functionally inactivated by the Src protein kinase. J Urol 2012 0.75
351 Re: bispecific small molecule-antibody conjugate targeting prostate cancer. J Urol 2014 0.75
352 Re: Brain Feminization Requires Active Repression of Masculinization via DNA Methylation. J Urol 2015 0.75
353 Re: CECR2 is involved in spermatogenesis and forms a complex with SNF2H in the testis. J Urol 2012 0.75
354 Re: SAHA Triggered MET Activation Contributes to SAHA Tolerance in Solid Cancer Cells. J Urol 2015 0.75
355 Re: targeting the regulation of androgen receptor signaling by the heat shock protein 90 cochaperone FKBP52 in prostate cancer cells. J Urol 2012 0.75
356 Re: simultaneous inhibition of two regulatory T-cell subsets enhanced interleukin-15 efficacy in a prostate tumor model. J Urol 2012 0.75
357 Re: TALEN-engineered AR gene rearrangements reveal endocrine uncoupling of androgen receptor in prostate cancer. J Urol 2014 0.75
358 Editorial comment. Urology 2010 0.75
359 Re: Fructose-1,6-bisphosphatase opposes renal carcinoma progression. J Urol 2015 0.75
360 Re: akt-mediated phosphorylation of Bmi1 modulates its oncogenic potential, e3 ligase activity, and DNA damage repair activity in mouse prostate cancer. J Urol 2012 0.75
361 Re: Gene signatures distinguish stage-specific prostate cancer stem cells isolated from transgenic adenocarcinoma of the mouse prostate lesions and predict the malignancy of human tumors. J Urol 2014 0.75
362 Re: missense mutations in SLC26A8, encoding a sperm-specific activator of CFTR, are associated with human asthenozoospermia. J Urol 2013 0.75
363 Re: Cox-2 inhibition enhances the activity of sunitinib in human renal cell carcinoma xenografts. J Urol 2013 0.75
364 Re: miR-182 and miR-203 induce mesenchymal to epithelial transition and self-sufficiency of growth signals via repressing SNAI2 in prostate cells. J Urol 2014 0.75
365 Re: PRC1 coordinates timing of sexual differentiation of female primordial germ cells. J Urol 2013 0.75
366 Re: An inducible model of abacterial prostatitis induces antigen specific inflammatory and proliferative changes in the murine prostate. J Urol 2012 0.75
367 Re: The Inhibitor of Differentiation Isoform Id1b, Generated by Alternative Splicing, Maintains Cell Quiescence and Confers Self-Renewal and Cancer Stem Cell-Like Properties. J Urol 2015 0.75
368 Re: VHL-Regulated miR-204 suppresses tumor growth through inhibition of LC3B-mediated autophagy in renal clear cell carcinoma. J Urol 2012 0.75
369 Re: Human Schlafen 5 (SLFN5) is a Regulator of Motility and Invasiveness of Renal Cell Carcinoma Cells. J Urol 2016 0.75
370 Re: Differential stage-dependent regulation of prostatic epithelial morphogenesis by Hedgehog signaling. J Urol 2014 0.75
371 Re: TRPA1 receptor modulation attenuates bladder overactivity induced by spinal cord injury. J Urol 2011 0.75
372 Re: Extracellular UDP enhances P2X-mediated bladder smooth muscle contractility via P2Y6 activation of the phospholipase C/Inositol trisphosphate pathway. J Urol 2013 0.75
373 Re: Characteristics of TRK-130 (naltalimide), a novel opioid ligand, as a new therapeutic agent for overactive bladder. J Urol 2014 0.75
374 Re: AKAP3 Degradation in Sperm Capacitation is Regulated by its Tyrosine Phosphorylation. J Urol 2016 0.75
375 Re: Loss of β1-integrin from urothelium results in overactive bladder and incontinence in mice: a mechanosensory rather than structural phenotype. J Urol 2013 0.75
376 Re: telomere length influences cancer cell differentiation in vivo. J Urol 2013 0.75
377 Re: Testosterone replacement effectively inhibits the development of experimental autoimmune orchitis in rats: evidence for a direct role of testosterone on regulatory T cell expansion. J Urol 2011 0.75
378 Re: Acquired platinum resistance enhances tumour angiogenesis through angiotensin II type 1 receptor in bladder cancer. J Urol 2012 0.75
379 Re: Collective and single cell behavior in epithelial contact inhibition. J Urol 2012 0.75
380 Re: A Feedback Regulation between miR-145 and DNA Methyltransferase 3b in Prostate Cancer Cell and Their Responses to Irradiation. J Urol 2015 0.75
381 Re: p21-activated kinase 6 (PAK6) inhibits prostate cancer growth via phosphorylation of androgen receptor and tumorigenic E3 ligase murine double minute-2 (Mdm2). J Urol 2013 0.75
382 Re: leptin signaling in GABA neurons, but not glutamate neurons, is required for reproductive function. J Urol 2014 0.75
383 Re: nonsteroidal selective androgen receptor modulators enhance female sexual motivation. J Urol 2011 0.75
384 A randomized placebo-controlled study of the efficacy of antimuscarinics in the treatment of pediatric overactive bladder and incontinence. Curr Urol Rep 2009 0.75
385 Re: Genomic Hallmarks of Localized, Non-Indolent Prostate Cancer. J Urol 2017 0.75
386 Re: Two Genes Substitute for the Mouse Y Chromosome for Spermatogenesis and Reproduction. J Urol 2016 0.75
387 Advancing the Translation of Stem Cells to Medicine. Stem Cells Transl Med 2016 0.75
388 Editorial: Bringing regenerative medicine therapies to the 21st century. Curr Stem Cell Res Ther 2014 0.75
389 Re: Stable Inhibitory Activity of Regulatory T Cells Requires the Transcription Factor Helios. J Urol 2016 0.75
390 Re: AKT-Mediated Stabilization of Histone Methyltransferase WHSC1 Promotes Prostate Cancer Metastasis. J Urol 2017 0.75
391 Re: Resistance to Docetaxel in Prostate Cancer is Associated with Androgen Receptor Activation and Loss of KDM5D Expression. J Urol 2016 0.75
392 Recent advances in the field of urology. Curr Urol Rep 2006 0.75
393 Re: Uropathogenic Escherichia coli induces chronic pelvic pain. J Urol 2011 0.75
394 Re: Targeted Fibrillar Nanocarbon RNAi Treatment of Acute Kidney Injury. J Urol 2016 0.75
395 Re: Reporter Nanoparticle that Monitors its Anticancer Efficacy in Real Time. J Urol 2016 0.75
396 Re: Targeted Molecular-Genetic Imaging and Ligand-Directed Therapy in Aggressive Variant Prostate Cancer. J Urol 2017 0.75
397 Controlled regulation of erythropoietin by primary cultured renal cells for renal failure induced anemia. J Urol 2012 0.75
398 Re: Infiltrating Neutrophils Promote Renal Cell Carcinoma (RCC) Proliferation via Modulating Androgen Receptor (AR) → c-Myc Signals. J Urol 2016 0.75
399 The effect of collagen hydrogel on 3D culture of ovarian follicles. Biomed Mater 2016 0.75
400 Re: Infiltrating Macrophages Increase RCC Epithelial Mesenchymal Transition (EMT) and Stem Cell-Like Populations via AKT and mTOR Signaling. J Urol 2016 0.75
401 Announcing a New Journal Section: Cord Blood. Stem Cells Transl Med 2017 0.75
402 Re: Phosphorylation-Induced Conformational Dynamics in an Intrinsically Disordered Protein and Potential Role in Phenotypic Heterogeneity. J Urol 2017 0.75
403 Re: A Tumor Mitochondria Vaccine Protects against Experimental Renal Cell Carcinoma. J Urol 2016 0.75
404 Re: Noncoding Mutations Target Cis-Regulatory Elements of the FOXA1 Plexus in Prostate Cancer. J Urol 2020 0.75
405 Stem cell advances and challenges. Curr Stem Cell Res Ther 2013 0.75
406 Re: Activation of Notch1 Synergizes with Multiple Pathways in Promoting Castration-Resistant Prostate Cancer. J Urol 2016 0.75
407 Re: A Structured Interdomain Linker Directs Self-Polymerization of Human Uromodulin. J Urol 2016 0.75
408 Tissue engineering in urology. World J Urol 2008 0.75
409 Re: Dietary Flavonoid Fisetin Binds to β-Tubulin and Disrupts Microtubule Dynamics in Prostate Cancer Cells. J Urol 2016 0.75
410 Re: Autologous Transplantation of Spermatogonial Stem Cells Restores Fertility in Congenitally Infertile Mice. J Urol 2020 0.75
411 This month in investigative urology. J Urol 2002 0.75
412 Re: Effects of Luteinizing Hormone Receptor Signaling in Prostate Cancer Cells. J Urol 2015 0.75
413 Re: Antagonists of Growth Hormone-Releasing Hormone Inhibit Proliferation Induced by Inflammation in Prostatic Epithelial Cells. J Urol 2017 0.75
414 Re: Comprehensive Mutagenesis of the FimS Promoter Regulatory Switch Reveals Novel Regulation of Type 1 Pili in Uropathogenic Escherichia coli. J Urol 2017 0.75
415 Re: Inactivation of the PBRM1 Tumor Suppressor Gene Amplifies the HIF-Response in VHL(-/-) Clear Cell Renal Carcinoma. J Urol 2017 0.75
416 Re: Mammalian Elongation Factor 4 Regulates Mitochondrial Translation Essential for Spermatogenesis. J Urol 2016 0.75
417 Bioengineered multilayered human corneas from discarded human corneal tissue. Biomed Mater 2015 0.75
418 Re: ARF Confers a Context-Dependent Response to Chemotherapy in Muscle-Invasive Bladder Cancer. J Urol 2017 0.75
419 Re: Activation of Notch1 Synergizes with Multiple Pathways in Promoting Castration-Resistant Prostate Cancer. J Urol 2017 0.75
420 Re: Loss of Tumor Suppressor KDM6A Amplifies PRC2-Regulated Transcriptional Repression in Bladder Cancer and Can be Targeted through Inhibition of EZH2. J Urol 2017 0.75
421 Re: Interruption of KLF5 Acetylation Converts its Function from Tumor Suppressor to Tumor Promoter in Prostate Cancer Cells. J Urol 2015 0.75
422 This month in investigative urology. J Urol 2008 0.75
423 Re: DNA Fragmentation Index (DFI) as a Measure of Sperm Quality and Fertility in Mice. J Urol 2020 0.75
424 Re: Expression Array Analysis of the Hepatocyte Growth Factor Invasive Program. J Urol 2016 0.75
425 Guest editors' introduction. Methods in tissue engineering. Methods 2009 0.75
426 A new era in stem cells translational medicine. Stem Cells Transl Med 2012 0.75
427 This month in investigative urology. J Urol 2007 0.75
428 Re: Mesenchymal Stem Cells are Recruited and Activated into Carcinoma-Associated Fibroblasts by Prostate Cancer Microenvironment-Derived TGF-β1. J Urol 2016 0.75
429 Re: Marked Protection against Acute Renal and Hepatic Injury after Nitrited Myoglobin + Tin Protoporphyrin Administration. J Urol 2016 0.75
430 Re: Long Noncoding RNA DRAIC Inhibits Prostate Cancer Progression by Interacting with IKK to Inhibit NF-κB Activation. J Urol 2020 0.75
431 Re: The Metabolic Co-Regulator PGC1α Suppresses Prostate Cancer Metastasis. J Urol 2017 0.75
432 Re: Bone Metastasis in Prostate Cancer: Recurring Mitochondrial DNA Mutation Reveals Selective Pressure Exerted by the Bone Microenvironment. J Urol 2016 0.75
433 Uro-Science. J Urol 2021 0.75
434 Re: Treatment of Diabetes Mellitus-Induced Erectile Dysfunction Using Endothelial Progenitor Cells Genetically Modified with Human Telomerase Reverse Transcriptase. J Urol 2016 0.75
435 Re: MicroRNA-141 Suppresses Prostate Cancer Stem Cells and Metastasis by Targeting a Cohort of Pro-Metastasis Genes. J Urol 2017 0.75
436 Re: Smooth Muscle Progenitor Cells Derived from Human Pluripotent Stem Cells Induce Histologic Changes in Injured Urethral Sphincter. J Urol 2017 0.75
437 Re: Genome-Wide Plasma DNA Methylation Features of Metastatic Prostate Cancer. J Urol 2020 0.75
438 Re: Sphaeropsidin A Shows Promising Activity against Drug-Resistant Cancer Cells by Targeting Regulatory Volume Increase. J Urol 2016 0.75
439 Re: Endogenous Formaldehyde is a Hematopoietic Stem Cell Genotoxin and Metabolic Carcinogen. J Urol 2016 0.75
440 Re: mTOR Contributes to ER Stress and Associated Apoptosis in Renal Tubular Cells. J Urol 2015 0.75
441 Re: Profiling of Long Non-Coding RNAs Identifies LINC00958 and LINC01296 as Candidate Oncogenes in Bladder Cancer. J Urol 2017 0.75
442 Re: Integrated Classification of Prostate Cancer Reveals a Novel Luminal Subtype with Poor Outcome. J Urol 2016 0.75
443 Re: Regulation of UHRF1 by Dual-Strand Tumor-Suppressor MicroRNA-145 (miR-145-5p and miR-145-3p): Inhibition of Bladder Cancer Cell Aggressiveness. J Urol 2016 0.75
444 Initial clinical results of the bioartificial kidney containing human cells in ICU patients with acute renal failure. Curr Urol Rep 2006 0.75
445 Applying Regenerative Medicine to Battlefield Injuries. N C Med J 2016 0.75
446 New Government Accountability Office Report on Regenerative Medicine Provides an Excellent Assessment of the Field. Stem Cells Transl Med 2015 0.75
447 Re: Quantification of external urethral sphincter and bladder activity during micturition in the intact and spinally transected adult rat. J Urol 2011 0.75
448 New frontiers in stem cell research and therapy. Curr Stem Cell Res Ther 2009 0.75
449 Re: Autophagy Defects Suggested by Low Levels of Autophagy Activator MAP1S and High Levels of Autophagy Inhibitor LRPPRC Predict Poor Prognosis of Prostate Cancer Patients. J Urol 2016 0.75
450 Uro-Science. J Urol 2021 0.75
451 Transforming the Approach to Cell-Based Therapies. Stem Cells Transl Med 2017 0.75
452 Re: Genome-Wide Association Study of Prostate-Specific Antigen Levels Identifies Novel Loci Independent of Prostate Cancer. J Urol 2017 0.75
453 Re: Comprehensive Analysis of Differentially Expressed Profiles of lncRNAs and circRNAs with Associated Co-Expression and ceRNA Networks in Bladder Carcinoma. J Urol 2016 0.75
454 This month in investigative urology. J Urol 2007 0.75
455 Re: Epigenetic Loss of AOX1 Expression via EZH2 Leads to Metabolic Deregulations and Promotes Bladder Cancer Progression. J Urol 2020 0.75
456 Re: Genome Engineering Uncovers 54 Evolutionarily Conserved and Testis-Enriched Genes That are Not Required for Male Fertility in Mice. J Urol 2016 0.75
457 Re: Rb1 and Trp53 Cooperate to Suppress Prostate Cancer Lineage Plasticity, Metastasis, and Antiandrogen Resistance. J Urol 2017 0.75
458 This month in investigative urology. J Urol 2002 0.75
459 Re: Cellular Uptake and Anticancer Activity of Carboxylated Gallium Corroles. J Urol 2016 0.75
460 Re: Combined Therapy with Adipose-Derived Mesenchymal Stem Cells and Ciprofloxacin against Acute Urogenital Organ Damage in Rat Sepsis Syndrome Induced by Intrapelvic Injection of Cecal Bacteria. J Urol 2016 0.75
461 Re: Inhibition of the Hexosamine Biosynthetic Pathway Promotes Castration-Resistant Prostate Cancer. J Urol 2016 0.75
462 Re: Calsperin is a testis-specific chaperone required for sperm fertility. J Urol 2011 0.75
463 Stem cells--brave new world? J Urol 2005 0.75
464 Re: Integrative Analyses Reveal a Long Noncoding RNA-Mediated Sponge Regulatory Network in Prostate Cancer. J Urol 2016 0.75
465 Re: N-Myc Drives Neuroendocrine Prostate Cancer Initiated from Human Prostate Epithelial Cells. J Urol 2016 0.75
466 Re: Androgen Receptor Antagonists Compromise T Cell Response against Prostate Cancer Leading to Early Tumor Relapse. J Urol 2017 0.75
467 Stem cells translational medicine: the journal of tomorrow is a reality today. Stem Cells Transl Med 2013 0.75
468 Re: Therapeutically Actionable PAK4 is Amplified, Overexpressed, and Involved in Bladder Cancer Progression. J Urol 2020 0.75
469 Re: Low CD38 Identifies Progenitor-Like Inflammation-Associated Luminal Cells that Can Initiate Human Prostate Cancer and Predict Poor Outcome. J Urol 2017 0.75
470 Stem cells translational medicine: exciting progress, growing partnerships, and new vehicles for information dissemination. Stem Cells Transl Med 2014 0.75
471 Re: The Metabolic Co-Regulator PGC1α Suppresses Prostate Cancer Metastasis. J Urol 2016 0.75